Top Story

PROMISE-GIM6: Fertility may be maintained with triptorelin, chemotherapy combination in early-stage breast cancer

September 23, 2014

Harold J. Burstein, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, associate professor of medicine at Harvard Medical School and an ASCO expert, discusses long-term results of the PROMISE-GIM6 trial. The study showed the addition of a luteinizing hormone-releasing analog to chemotherapy preserved long-term ovarian function in premenopausal women with early-stage breast cancer.

figure In the Journals

Lung cancer diagnostic test loses specificity in areas with endemic lung infections

September 23, 2014
PET imaging with fludeoxyglucose F 18 less reliably diagnosed malignant lung lesions in populations with endemic infectious lung disease, according to results of a…
In the Journals

TH-302 demonstrates encouraging activity in soft tissue sarcoma

September 23, 2014
The investigational hypoxia-targeted drug TH-302 was associated with PFS, OS and tumor response rates that compared favorably with other first-line agents for soft…
Meeting News Coverage

Cancer incidence in type 1 diabetes similar to general population

September 23, 2014
Site-specific cancer patterns in type 1 diabetes largely follow incidence in patients with type 2 diabetes, but more minimal, and do not drastically differ from general…
More News Headlines »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
figure

PROMISE-GIM6: Fertility may be maintained with triptorelin, chemotherapy combination in early-stage breast cancer

September 23, 2014
Harold J. Burstein, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, associate professor of medicine at…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »